Cardiovascular Outcomes : Treatments that offer cardiovascular benefits are increasingly preferred in T2D management due to the high risk of cardiovascular disease in this population
Patients who become pregnant unexpectedly while on GLP-1 therapy should discontinue immediately and contact their healthcare provider
Related Reading Genetic Testing 101 What You Need To Know Before Getting Tested What Genetic Factors Determine How Much Sleep You Need Each Night Lifemd Ozempic Eden Ozempic Medical and Editorial Standards Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims
CONCLUSIONS CONFLICTS OF INTEREST In the last 5 years Adie Viljoen has received lecture honoraria and/or travel support and/or conducts clinical trials funded by: Amarin, Amgen, Astra Zeneca, Boehringer Ingleheim, Daiichi-Sankyo, Lilly, Menarini, NewAmsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, Takeda, and Tosoh
As of July 2025, many Aetna plans no longer cover Zepbound for weight loss
Glucagon-like peptide-1 (GLP-1) receptor agonists are established treatments for type 2 diabetes mellitus and obesity in the UK, typically administered via subcutaneous injection
